Phase 2 study of ACH-4471 in Paroxysmal-nocturnal-haemoglobinuria patients who sub-optimally respond to treatment with eculizamab, the current standard of care.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 02 Nov 2017 According to Achillion media release, company plans to initiate the trial in first half of 2018.
- 13 Sep 2017 New trial record